Hypokalemia and thrombocytosis could occur upon conversion of severe megaloblastic anemia to normal erythropoiesis with methylcobalamin therapy
After spending time on the FDA's Category 2 list flagged for "significant safety concerns" BPC-157 is now being removed from that restrictive classification and scheduled for a Pharmacy Compounding Advisory Committee (PCAC) review on July 23, 2026
It's not positioned as a cure, but rather as a supportive element in a broader gut health strategy that includes whole foods, hydration, and mindfulness around inflammation triggers
Russell AL, Kennedy AM, Spuches AM, Gibson WS, Venugopal D, Klapper D, Srouji AH, Bhonsle JB, Hicks RP (2011) Determining the effect of the incorporation of unnatural amino acids into antimicrobial peptides on the interactions with zwitterionic and anionic membrane model systems
Our team monitors your response during and after the injection